Elevated PSPC1 and KDM5C expression indicates poor prognosis in prostate cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men.
• Epigenetic aberrations, including histone modification, are implicated in PCa development.
• Lysine Demethylase 5C (KDM5C) is known to drive PCa progression via epithelial-mesenchymal transition.

Purpose of the Study:

• To investigate the role of Paraspeckle Component 1 (PSPC1) in PCa.
• To explore the relationship between KDM5C and PSPC1 in PCa.
• To determine the prognostic significance of PSPC1 in prostate tumors.

Main Methods:

• Immunohistochemical analysis of KDM5C and PSPC1 expression in two independent prostate cancer cohorts (432 and 205 tumors).
• Correlation analysis between KDM5C and PSPC1 expression levels.
• Evaluation of PSPC1 expression in relation to clinicopathological features and patient survival.

Main Results:

• PSPC1 expression correlates significantly with KDM5C expression.
• PSPC1 is upregulated in primary and metastatic PCa.
• Elevated PSPC1 levels are associated with higher tumor grade, advanced T-stage, and poorer biochemical recurrence-free survival.
• PSPC1 serves as an independent prognostic marker for PCa.

Conclusions:

• KDM5C and PSPC1 are jointly involved in prostate cancer progression.
• Targeting KDM5C and PSPC1 with selective inhibitors may offer a novel therapeutic strategy for PCa.